Skip to main content
. 2021 May 21;106(8):2171–2186. doi: 10.1210/clinem/dgab361

Table 6.

Estimated changes from baseline in patient-reported outcomes by treatment arm

Variable Placebo 1 mg/day 5 mg/day 15 mg/day P value (5 mg/day vs Placebo) P value (any effect)
IPSS
Symptom −0.07 (−1.01, 0.87) −1.48 (−2.59, −0.38) 0.08 (−0.82, 0.99) 0.13 (−1.31, 1.57) 0.80 0.10
 Quality of Life Due to Urinary Symptoms −0.02 (−0.25, 0.21) −0.22 (−049, 0.06) −0.02 (−0.25, 0.20) −0.17 (−0.53, 0.18) 0.99 0.58
FACIT-F −0.74 (−2.89, 1.41) 1.52 (−0.98, 4.03) −0.11 (−2.17, 1.95) 0.47 (−2.83, 3.77) 0.66 0.54
PANAS
 Positive Affect 0.79 (−1.12, 2.70) 0.57 (−1.63, 2.78) 1.15 (−0.66, 2.95) −0.45 (−3.36, 2.46) 0.78 0.83
 Negative Affect −1.52 (−2.62, −0.42) −1.78 (−3.06, −0.50) −0.14 (−1.19, 0.91) −2.19 (−3.90, −0.49) 0.06 0.08